Cancer Advisor

Edited and Updated: June 2026  Caution to the Reader: This is a complex, evolving topic rooted in molecular biology and evolutionary dynamics. The material below has been distilled for clinical accessibility while preserving strict mechanistic accuracy. Key conceptual frameworks from the Care Oncology Clinic (COC) protocol and Thomas Seyfried’s press–pulse model are integrated throughout. Introduction Clinicians utilizing a metabolic framework often combine 4–5 repurposed prescription agents with 4–5 nutraceuticals. While this approach frequently yields 1–2 years of sustained, stable response, acquired resistance can emerge rapidly, turning stable disease into aggressive progression. When this occurs, critical clinical questions arise: How should the regimen be modified? Should mechanistically similar agents be cycled more frequently? Should dosing be intermittent rather than continuous? What ...

Abstract Background Despite remarkable advances in targeted therapies, immunotherapy, and molecular diagnostics, therapeutic resistance remains the principal cause of cancer-related mortality. Traditional precision oncology has focused predominantly on genomic drivers; however, accumulating evidence demonstrates that metabolic adaptation, immune evasion, and tumor microenvironment remodeling are equally critical determinants of treatment failure. Cancer cells exhibit extraordinary metabolic plasticity, enabling survival despite chemotherapy, targeted therapy, radiation, and immunotherapy. Objective To propose an integrated Personalized Metabolic Oncology (PMO) framework that combines genomic profiling, metabolic phenotyping, immune characterization, and tumor ecosystem analysis to overcome therapeutic resistance and improve long-term cancer control. Methods This narrative review synthesizes contemporary evidence from cancer metabolism, immunometabolism, systems oncology, and precision ...